Dynavax Technologies Co. (NASDAQ:DVAX) short interest falls by … – Best Stocks
There was a significant drop in the number of investors who held short positions in Dynavax Technologies Co. during November (NASDAQ: DVAX). As of November 15, there were 15,730,000 shares available for a short sale; as of November 30, there were only 13,820,000 shares available, which is a decrease of 12.1% from the total number of shares that were available on November 15. The days-to-cover ratio is currently at 7.4 days, based on an average trading volume of 1,880,000 shares. This number was arrived at after doing some calculations.
Important shareholders have just recently made adjustments to their existing stock holdings. The holdings of Dynavax Technologies, managed by Advisors Asset Management Inc., increased by 498.0% during the first three months of 2018. During the preceding quarter, Advisors Asset Management Inc. purchased an additional 1,967 shares, bringing the total number of shares in the biopharmaceutical company they own to 2,362. The current market price for these shares is $26,000. Quantbot Technologies LP saw a 940.7% increase in its holdings of Dynavax Technologies during the first three months of 2018. Quantbot Technologies LP presently possesses 2,508 biopharmaceutical company shares, with a combined market value of $27,000. This is because the company purchased an additional 2,267 shares during the most recent quarter of the fiscal year. The Banque Cantonale Vaudoise increased the total amount it had invested in Dynavax Technologies during the second quarter by investing approximately $67,000 in the company. This brought the total amount of the investment to a higher level.
Creative Financial Designs manage the investment portfolio, Inc. ADV increased its holdings in Dynavax Technologies by 1,875.0% over the third quarter. As a result of the purchase of an additional 7,500 shares during the preceding quarter, Creative Financial Designs, Inc. (ADV) is now the owner of the stock of the biopharmaceutical business. This gives the stock a value of $82,000, which brings the total number of shares owned to a total of 15,000 shares. Last but not least, during the third quarter, KBC Group NV paid approximately $100,000 to acquire a new interest in Dynavax Technologies. This should not be considered the least important item on this list. The company did not limit its investments to just this one thing. At present, institutions own 96.66% of the company’s total outstanding shares.
The company’s Chief Operating Officer, David F. Novack, sold 52,204 shares of company stock on Tuesday, November 8. This is another development that is relevant to this topic. The sale of the stock resulted in total revenue of 650,983.88 dollars, with the average price that each share could fetch being $12.47. As soon as the deal is finalized, the chief operating officer will become the owner of 2,066 company shares, which have a combined value of approximately $25,763.02. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. The company’s Chief Operating Officer, David F. Novack, sold 52,204 shares of company stock on Tuesday, November 8. This is another development that is relevant to this topic. The sale of the stock resulted in total revenue of 650,983.88 dollars, with the average price that each share could fetch being $12.47. The chief operating officer has a direct ownership stake in the company that is equal to 2,066 shares, and the value of those shares based on the company’s most recent market price is approximately $25,763.02. One can access the legal file containing the disclosure of the transaction by going to the Securities and Exchange Commission (SEC) website. Andrew A. F. Hack, also a company director, sold 1,500,000 shares of the company’s stock on Tuesday, December 6. The stock was bought and sold for a total value of $17,400,000.00, with the average price per share being $11.60. This resulted in revenue for the company. Following the successful conclusion of the transaction, the director now directly owns 3,915,000 shares of the company’s stock, which together have a value of approximately $45,414,000. Disclosures that are related to the sale might be found in this section of the website. Corporate insiders currently hold an equity stake in the company equivalent to 9.31% of the total equity.
Many different equity analysts have recently provided their opinions on the DVAX stock. Goldman Sachs Group gave Dynavax Technologies a “buy” rating. It reduced its price target for the company from $24.00 to $21.00 in a report about the company that was published on Friday, November 4. The report was about research that was conducted on Dynavax Technologies. TheStreet lowered its rating of Dynavax Technologies from “b-” to “c+” on Thursday, September 1, because the company has been performing so poorly. The recommendation that StockNews.com had previously given for Dynavax Technologies was changed from a “buy” rating to a “hold” rating in a report published on November 7. JMP Securities returned to the market on Tuesday, September 27, and began covering Dynavax Technologies after being absent for an extended period. They have given the company an “outperform” rating and determined that its price target should be $22.00. While one analyst recommends that investors keep their current position with the company, three others have given it a buy rating, so investors can choose which recommendation to follow. The website Bloomberg.com reports that the company has been given an average recommendation of “Moderate Buy” and that the price at which it is anticipated to reach consensus is $23.67.
When trading started on Friday, the price of a share of DVAX stock was $11.17. During the last year and a half, the price of a Dynavax Technologies product has varied between $7.26 and $17.48, with an average price of $17.48. The company has a P/E ratio of 5.40, and its beta value is 1.34. Its market capitalization is currently sitting at $1.43 billion at the moment. The moving average of the company’s stock price over the past 200 days is $12.32, while the moving average over the past 50 days is $11.83. The calculation reveals a debt-to-equity ratio of 0.44, a current ratio of 3.82, and a quick ratio of 3.40.
The most recent quarterly earnings report for Dynavax Technologies was released on November 3, and it is listed under the ticker symbol “DVAX.” You can find more information about the company here. The quarterly profit report for the biopharmaceutical company came in at $0.43 per share, which was $0.43 higher than the projections made by analysts by $0.10. Dynavax Technologies had a return on equity of 90.54%, while the net margin for the company was 44.35%. The results of the company’s sales for the quarter came in at $167.74 million, which is significantly higher than the industry experts’ prediction of $149.99 million for the company’s sales for the quarter. During the current fiscal year, Dynavax Technologies is expected to bring in revenue equal to $1.84 per share. Professionals in the relevant industry made these projections.
Over the last nine years, Elaine has managed investment portfolio using fundamental analysis and value investing, emphasizing long-term time horizons.
DISCLAIMER
Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.
READ MORE
Follow us on Social Media
Facebook – YouTube – Twitter
Write for us
Finance – Business
Categories
Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks
Data and Tools
Quote
Target
Wealth
Converter
Dow Jones Today
Best Stocks to Buy Now
We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.
Get free stock recommendations and real-time news. Our portfolio has returned over 100% in 2020.
© 2022 Best Stocks
© 2022 Best Stocks